[环己基(羟基)亚甲基]丙二腈 | 553672-03-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: [环己基(羟基)亚甲基]丙二腈
• 英文名称: [cyclohexyl(hydroxy)methylidene]propanedinitrile
• 英文别名: 2-[Cyclohexyl(hydroxy)methylene]malononitrile；2-[cyclohexyl(hydroxy)methylidene]propanedinitrile
• CAS: 553672-03-0
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: DCHGDYPJCSCORE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [环己基(羟基)亚甲基]丙二腈 在 ammonium hydroxide 、 硫酸 、 硫化氢 、 双氧水 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 N,N-二甲基乙酰胺 、 苯 为溶剂， 反应 1.5h， 生成 tert-butyl 4-[4-(3-cyclohexyl-4-oxo-4,5-dihydro[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-3-methoxyphenyl]piperazine-1-carboxylate
  参考文献：
  名称：

  Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation

  摘要：

  The synthesis and structure-activity relationship studies of isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors are discussed. The pharmacokinetic profile of 10 and 21 with adequate CNS penetration, required for in vivo Parkinson's disease models, are disclosed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.025
• 作为产物：
  描述：

  环己甲酰氯 在 sodium hydride 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 以77%的产率得到[环己基(羟基)亚甲基]丙二腈
  参考文献：
  名称：

  [EN] PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS
  [FR] DERIVES DE PYRIDINYL-PYRAZOLO-PYRIMIDINONES INHIBITEURS DE LA PHOSPHODIESTERASE VII

  摘要：

  为了提供选择性抑制PDE 7的化合物，从而增强细胞内cAMP水平。因此，该化合物对治疗各种疾病如过敏病、炎症性疾病或免疫疾病具有用处。该化合物是由以下式(IA)或(IB)表示的吡啶基吡唑吡嘧啶酮化合物：特别地，R1是环己基或环庚基，R2是甲基；R3是一个基团：-NR5R6或-S(O)0-2R8；氢原子；硝基基团；氰基；卤原子；杂环基团；而R4是甲氧基或乙氧基。

  公开号：

  WO2004111054A1

文献信息

• Pyridinylpyrazolopyrimidinone derivatives as pde 7 inhibitors
  申请人：Inoue Hidekazu

  公开号：US20060128728A1

  公开（公告）日：2006-06-15

  To provide the compounds inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is pyridinylpyrazolopyrimidinone compound represented by the following formula (IA) or (IB): especially, R 1 is cyclohexyl or cycloheptyl group, R 2 is methyl; R 3 is a group: —NR 5 R 6 or —S(O) 0-2 R 8 ; hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; and R 4 is methoxy or ethoxy group.

  为了提供具有选择性抑制PDE7的化合物，从而增强细胞内cAMP水平。因此，该化合物可用于治疗各种疾病，例如过敏性疾病、炎症性疾病或免疫性疾病。该化合物是由以下式子（IA）或（IB）表示的吡啶基嘧啶酮化合物：特别地，R1是环己基或环庚基，R2是甲基；R3是一种基团：—NR5R6或—S（O）0-2R8；氢原子；硝基；氰基；卤素原子；杂环基团；R4是甲氧基或乙氧基。
• Pyrazolopyrimidinone derivatives having PDE7 inhibiting action
  申请人：Inoue Hidekazu

  公开号：US20050148604A1

  公开（公告）日：2005-07-07

  Pyrazolopyrimidinone derivatives expressed by the following general formula (IA) or (IB): and the following general formula (IA′) or (IB′): where the symbols are as disclosed in the specification, are provided as desired compounds. These compounds have the action of selectively inhibiting PDE7, thereby increasing the intracellular cAMP level and inhibiting the activation of T cells. Thus, they are useful for prevention and treatment of various allergic diseases and inflammatory or immunological diseases.

  本发明提供了以下通式(IA)或(IB)所表达的吡唑并嘧啶酮衍生物，以及以下通式(IA′)或(IB′)所表达的吡唑并嘧啶酮衍生物：其中所述符号如本说明书所披露的那样，作为所需的化合物提供。这些化合物具有选择性地抑制PDE7的作用，从而增加细胞内cAMP水平并抑制T细胞的活化。因此，它们对于预防和治疗各种过敏性疾病和炎症或免疫性疾病是有用的。
• 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action
  申请人：Ausbio Pharma Co., Ltd.

  公开号：US07268128B2

  公开（公告）日：2007-09-11

  Pyrazolopyrimidinone derivatives expressed by the following general formula (IA) or (IB): where the symbols are as disclosed in the specification, are provided as desired compounds. These compounds selectively inhibiting PDE7, thereby increasing the intracellular cAMP level and inhibiting the activation of T cells. Thus, these compounds are useful for prevention and treatment of various allergic diseases and inflammatory or immunological diseases.

  以下一般式（IA）或（IB）所表示的吡唑并嘧啶酮衍生物： 其中符号如说明书所述，作为所需的化合物提供。这些化合物选择性地抑制PDE7，从而增加细胞内cAMP水平并抑制T细胞的活化。因此，这些化合物对于预防和治疗各种过敏性疾病和炎症或免疫性疾病非常有用。
• PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS
  申请人：Inoue Hidekazu

  公开号：US20070270419A1

  公开（公告）日：2007-11-22

  To provide the compounds inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is pyridinylpyrazolo-pyrimidinone compound represented by the following formula (IA) or (IB): especially, R 1 is cyclohexyl or cycloheptyl group, R 2 is methyl; R 3 is a group: —NR 5 R 6 or —S(O) 0-2 R 8 ;hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; and R 4 is methoxy or ethoxy group.

  提供有选择性地抑制PDE 7的化合物，从而增强细胞cAMP水平。因此，该化合物可用于治疗各种疾病，例如过敏性疾病、炎症性疾病或免疫性疾病。该化合物是由以下式子（IA）或（IB）表示的吡啶基吡唑嘧啶酮化合物：其中，特别地，R1为环己基或环庚基，R2为甲基；R3为一种基团：-NR5R6或-S（O）0-2R8；氢原子；硝基；氰基；卤素原子；杂环基团；R4为甲氧基或乙氧基。
• PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY
  申请人：Daiichi Suntory Pharma Co., Ltd.

  公开号：EP1454897A1

  公开（公告）日：2004-09-08

  Pyrazolopyrimidinone derivatives expressed by the following general formula (IA) or (IB): and the following general formula (IA') or (IB'): where the symbols are as disclosed in the specification, are provided as desired compounds. These compounds have the action of selectively inhibiting PDE7, thereby increasing the intracellular cAMP level and inhibiting the activation of T cells. Thus, they are useful for prevention and treatment of various allergic diseases and inflammatory or immunological diseases.

  由以下通式（IA）或（IB）表示的吡唑嘧啶酮衍生物： 和以下通式（IA'）或（IB'）表示的吡唑嘧啶酮衍生物： 其中的符号如说明书中所披露的，作为所需的化合物提供。 这些化合物具有选择性抑制 PDE7 的作用，从而提高细胞内 cAMP 水平并抑制 T 细胞的活化。因此，它们可用于预防和治疗各种过敏性疾病和炎症性或免疫性疾病。